MARKET OUTLOOK Female infertility is typically defined as the inability to achieve pregnancy after one year of attempting conception. A wide range of factors may cause female infertility, such as…
Market Overview In a landmark FDA ruling in March 2017, Ocrevus became the first disease-modifying therapy (DMT) approved for the treatment of primary-progressive multiple sclerosis (PP-MS)…
The psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe patient population, who cannot be adequately controlled with topical agents…
MARKET OUTLOOK Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the…
MARKET OUTLOOK Venous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), represents a significant medical and economic burden. Although, the launch of the…
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded…
Rheumatoid arthritis (RA) treatment is typically initiated with cost-effective conventional DMARDs, such as methotrexate. The U.S. market for conventional DMARD-refractory RA patients is crowded…
The algorithms for treating psoriatic arthritis (PsA) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…
Market Overview Ocrevus is the latest disease-modifying therapy (DMT) to launch for the treatment of relapsing forms of multiple sclerosis (MS) in the United States, and easily one of the most…
The algorithms for treating psoriatic arthritis (PsA) are unique among rheumatic diseases because most PsA patients receive prior treatment by dermatologists for psoriasis, with many of the same…
The chronic obstructive pulmonary disease (COPD) market is experiencing increased competition as newer combination therapies vie with long-marketed stalwarts Spiriva, Advair, and Symbicort. Current…
MARKET OUTLOOK The chronic obstructive pulmonary disease (COPD) market is experiencing increased competition as newer combination therapies vie with long-marketed stalwarts Spiriva, Advair, and…
A large array of clinically unique disease-modifying therapies (DMTs) is approved for the treatment of multiple sclerosis (MS) in the United States. Competition in this crowded market has…
Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the EU5. OA pain treatment decisions are driven primarily by rheumatologists,…
Copy/Paste the key inputs from the product brochure, per guidance from Solutions. Osteoarthritic (OA) pain is a prevalent subtype of chronic pain, affecting more than 43 million individuals in the…